In several human cancers, ErbB2 over-expression facilitates the formation of constitutively active homodimers resistant to internalization which results in progressive signal amplification from the receptor, conducive to cell survival, proliferation, or metastasis. Here we report on studies of the influence of ErbB2 over-expression on localization and signaling in polarized Caco-2 and MDCK cells, two established models to study molecular trafficking. In these cells, ErbB2 is not over-expressed and shares basolateral localization with ErbB3. Over-expression of ErbB2 by transient transfection resulted in partial separation of the receptors by relocalization of ErbB2, but not ErbB3, to the apical surface, as shown by biotinylation of the apical or basolateral surfaces. These results were confirmed by immunofluorescence and confocal microscopy. Polarity controls indicated that the relocalization of ErbB2 is not the result of depolarization of the cells. Biotinylation and confocal microscopy also showed that apical, but not basolateral ErbB2 is activated at tyrosine 1139. This phosphotyrosine binds adaptor protein Grb2, as confirmed by immunoprecipitation. However, we found that it does not initiate the canonical Grb2-Ras-Raf-Erk pathway. Instead, our data supports the activation of a survival pathway via Bcl-2. The effects of ErbB2 over-expression were abrogated by the humanized anti-ErbB2 monoclonal antibody Herceptin added only from the apical side. The ability of apical ErbB2 to initiate an altered downstream cascade suggests that subcellular localization of the receptor plays an important role in regulating ErbB2 signaling in polarized epithelia.

The treatment and/or prevention of cancer by selective down regulation of cancer causing gene (oncogene) transcription would represent a significant advance in the area of anticancer drug design. Non-canonical higher order DNA structures formed in oncogene promoter regions are novel targets for the modulation of oncogene expression. An obvious advantage of selectively targeting oncogene expression would be that general cytotoxicity would be minimized and the negative side effects of current chemotherapy approaches could be minimized or eliminated. To provide a foundation for the design of drugs that target oncogene promoter G-quadruplexes and i-Motifs, the basic understanding is required of the folding of guanine and cytosine rich sequences and how small molecules bind to these structures. The research reported here focuses on higher order DNA structures of two oncogenes, K-ras that is overexpressed in pancreatic cancer, and Bcl-2 that is overexpressed in a number of cancers, and one non-oncogene, HAR1. We have probed the overall structure, stability, and binding of a model drug compounds to G-quadruplex and i-Motif DNA structures in these genes. The overall objectives of this work were: 1) to understand the relationship between oligonucleotide sequence and intramolecular folding topology and stability, and 2) to understand the mechanisms for the selective binding of small molecules to these structures. Biophysical techniques including: microcalorimetry, spectroscopy, analytical ultracentrifugation, gel electrophoresis, and computational methods were used to characterize both the folding and the binding interactions. We have shown that the native K-ras purine and pyrimidine rich sequences form stable G-quadruplexes and i-Motifs. We have also characterized four G-rich sequences found within the reading frame of the human HAR1 gene. This is the first report on the formation of stable G-quadruplex motifs within the RF of any gene. The model drug, TMPyP4, binds to the Bcl-2, K-ras, and HAR1 G-quadruplexes by two different binding modes, end binding and intercalation. The significance of this research is that the results of the K-ras and Bcl-2 studies could lead to the design of drugs that selectively target oncogenes while the HAR1 results could provide new approaches to the treatment of Schizophrenia and Alzheimer’s disease.

Apoptosis is essential for cellular homeostasis and is also a pathologic feature of various diseases. The balance between Bcl-2 family proteins determines whether a cell will live or die. Bax, a member of the BCL-2 family proteins, is a pro-apoptotic protein that exists in both a soluble, cytoplasmic form and a membrane-bound form. Upon apoptotic stimuli, Bax undergoes a conformational change and translocates to the mitochondria, initiating apoptotic events. However, little is known about whether Bax is involved in the regulation of mitochondrial function under non-apoptotic conditions, and how Bax binds to mitochondria to exert its activity. Here, we investigate the role of Bax in the regulation of mitochondrial function under non-apoptotic conditions and explore the molecular mechanisms for Bax binding mitochondria under apoptotic stimuli. Using Bax-containing and Bax-deficient (Bax⁻/⁻) HCT-116 cells, we examined Bax cellular localization and its effects on mitochondria bioenergetics, and also tested whether over-expression of full-length Bax in Bax⁻/⁻ cells would recover mitochondrial metabolic activity. To determine the effects of Bax localization upon mitochondrial function, we measured citrate synthase activity and ATP generation. We showed that Bax localized to the outer and inner mitochondrial membranes in non-apoptotic cells, enabling the activity of citrate synthase and the generation of ATP. Loss of Bax led to impairment of respiring mitochondria morphology and reduced oxidative capacity, all of which was restored by expression of full-length or C-terminal-deleted Bax. These findings indicate that under non-apoptotic conditions, the constitutive expression of Bax is necessary for mitochondrial bioenergetics. To determine the molecular mechanisms for Bax binding mitochondria under apoptotic stimuli, we previously performed in silico-mutagenesis and predicted that Lysines 189/190, in the C-terminal [alpha]9 helix, could regulate Bax binding to mitochondria. We demonstrated here that these lysines are the structural elements responsible for controlling how Bax interacts with the mitochondrial membrane. Expression of full-length Bax led to mitochondrial translocation and apoptosis, whereas deletion of the [alpha]9 helix resulted in cytosolic retention and dramatically reduced cell death. Mutation of the two lysine residues changed how Bax bound to mitochondrial membranes. We replicated the results achieved with full-length Bax by attaching the [alpha]9 helix of Bax to GFP or to a regulatory element, the degradation domain (DD), and induced apoptosis upon expression in cells. We demonstrated that the [alpha]9 helix alone promoted the mitochondrial translocation of Bax and increased apoptosis. These results indicate that the C-terminal [alpha]9 helix could be further studied for use in cancer therapies. Overall, we have demonstrated that the constitutive expression of the inactive form of Bax in non-apoptotic cells is necessary for mitochondrial bioenergetics, and have identified the C-terminal [alpha]9 helix of Bax as the effector domain of apoptotic function.

No description available.

No description available.

No description available.

La mort cellulaire programmée est un processus par lequel les cellules participent activement à leur propre mort. Ce mécanisme est très important au niveau du développement et de la survie de tous les organismes et est régulé par une panoplie de protéines. Parmi les protéines régulatrices figurent la protéine ±Bax Inhibitor-1¿ que l'on retrouve autant chez les cellules animales que végétales. Cette protéine est surtout connue et identifiée par son effet inhibiteur de l'action de la protéine Bax, protéine principalement retrouvée dans les cellules animales qui, lorsque surexprimée, active la mort cellulaire. L'analyse des séquences d'acides aminés de BI-1 provenant de cinq différentes espèces de plantes suggère l'existence de sept domaines transmembranaires avec la présence de résidus chargés dans certains domaines ce qui laisse supposer des interactions avec d'autres molécules. / D'un autre côté, le haut niveau de conservation de l'extrémité C-terminale à travers l'évolution dénote son importance fonctionnelle potentielle. Suite à ces constatations, l'étude de la relation entre la structure et la fonction de la protéine BI-1 a été entreprise afin d'identifier des sites potentiellement importants dans la séquence de la protéine BI-1 qui lui permet de contrer l'action de Bax. Nous avons démontré, par délétion graduelle de l'extrémité C-terminale, que cette région est importante pour la fonction de BI-1. Cette extrémité délètée, d'aussi peu que quatre acides aminés, modifie la fonction de la protéine et une délétion de onze acides aminés abolit complètement son effet cytoprotecteur. Nous avons aussi établi, par mutagenèse dirigée, que deux acides aminés chargés sur quatre dans le septième domaine transmembranaire sont importants pour la fonction de BI-1. Finalement, nous avons proposé, suite à l'étude par mutagenèse aléatoire, l'importance possible du cinquième domaine transmembranaire dans la fonction de la protéine BI-1. Nous pouvons donc conclure que la capacité de BI-1 à inhiber l'effet létal de Bax dépend de sa structure.

Les agents anti-microtubules (MTAs), comme les taxanes et les vinca-alcaloïdes, sont des anticancéreux largement utilisés en pratique clinique. Ils agissent d'une part en perturbant les fonctions du réseau microtubulaire, conduisant à un arrêt du cycle cellulaire. D'autre part, à côté de cet effet anti-prolifératif, les MTAs sont capables d'induire divers signaux responsables de l'exécution du programme apoptotique via la voie mitochondriale intrinsèque. La famille Bcl-2 joue un rôle primordial dans l'induction de l'apoptose par ces agents. Aussi, au cours de ce travail, nous nous sommes d'abord intéressés à l'origine de la diminution de Bcl-2 lors de l'apoptose médiée par la vinorelbine. Nous avons ainsi mis en évidence la régulation transcriptionnelle de bcl-2 grâce à l'identification d'un nouveau site de liaison de p53 sur le promoteur de bcl-2. Dans un second temps, nous avons évalué l'influence de la famille Bcl-2 dans la réponse aux MTAs. En effet, nous nous sommes focalisés sur la sensibilité paradoxale aux MTAs de certaines tumeurs surexprimant Bcl-2, in vitro et in vivo chez la souris nude. Nous avons montré l'implication de Bim dans cette augmentation de sensibilité, qui agit en perturbant le réseau mitochondrial. Enfin, nous avons investigué le mécanisme moléculaire liant la surexpression de Bcl-2 et celle de Bim. Nous avons montré que la surexpression de Bcl-2, en inhibant l'activité transcriptionnelle de p53, permettait une meilleure activité du facteur de transcription FoxO3a, principal acteur de la régulation génique de Bim. / Microtubule targeting agents (MTAs), such as taxanes and vinca-alkaloïds, are anticancer drugs widely used in clinical practice. Firstly, they are known to disturb functions of microtubular network, leading to cell cycle arrest. On the other hand, beside this anti-proliferative effect, MTAs are able to trigger signaling cascades leading to apoptosis execution, through intrinsic mitochondrial pathway. Bcl-2 family proteins play a crucial role in induction of MTAs-induced apoptosis. In this work, we first studied the origin of Bcl-2 downregulation in vinorelbine-mediated apoptosis. We thus highlighted a transcriptional mechanism through the identification of a novel p53 binding site in the bcl-2 promoter. Second, we evaluated the influence of Bcl-2 family in response to MTAs. Indeed, we focused on paradoxical sensitivity to MTAs of some tumors overexpressing Bcl-2, in vitro and in vivo in nude mouse. Bim was involved in this enhanced sensitivity, by disrupting the mitochondrial network. We then investigated the molecular mechanism linking Bcl-2 and Bim overexpressions. We showed that Bcl-2 overexpression, by inhibiting the transcriptional activity of p53, leads to an increase in activity of the transcription factor FoxO3a, the main actor in Bim transcriptional regulation. Our work underlines the importance of Bcl-2 family and especially Bim as potential biomarker in predicting MTA's efficacy.

La macro-autophagie est une voie catabolique conservée dans l’évolution permettant la dégradation des organites endommagés ou vieux, des protéines à longue durée de vie ou agrégées et des portions du cytosol pour le recyclage métabolique afin de maintenir l'homéostasie cellulaire. L'absence d'autophagie est fréquemment observée dans de nombreuses pathologies incluant les cancers et les maladies neurodégénératives. Beclin 1, un suppresseur de tumeur,est une protéine clé dans la régulation de l’autophagie et participe à la nucléation de l’autophagosome. Beclin 1 est une protéine “BH3-only” pouvant interagir avec le site de fixation au domaine BH3 présent dans la protéine Bcl-2 et ses homologues. Cette interaction inhibe l’autophagie. Certains agents pharmacologiques tels qu’ABT737, appelés«BH3 mimetics», occupent le site de fixation du domaine BH3 de façon compétitive pour perturber l'interaction inhibitrice entre Beclin 1 et Bcl-2/Bcl-XL. Ceci permet à Beclin 1 de maintenir l’activité classe IIIphosphatidylinositol-3-kinase de Vps34 pour la formation du phagophore. L'autophagie est un processus finement régulé par de nombreux complexes protéiques. Les senseurs de la charge énergétique comme l’AMP-dependant kinase(AMPK), la cible mammalienne de la rapamycine (mTOR), la Sirtuin1 (SIRT1) ou les voies d’intégration du stress telles que celles impliquant l'inhibiteur des kinases NF-κB (IκBα) (IKK) et le suppresseur de tumeur p53, ont tous un impact majeur dans la régulation de l'autophagie. Dans de nombreux paradigmes de stimulation autophagique, ils semblent tous agir en amont de la dissociation Beclin 1-Bcl-2. Nos résultats révèlent qu’ABT737 stimule plusieurs voies pro-autophagiques pour obtenir une efficacité optimale. Ces résultats placent la SIRT1, AMPK / mTOR, HDM2et IKK en aval de la dissociation du complexe Beclin 1-Bcl-2. Cette étude démontre que les BH3-mimetics activent des voies multiples de stimulation de l’autophagie, peut-être en raison du degré élevé de connectivité qui existe entre les complexes protéiques de régulation de l’autophagie. Cela signifie qu’un effet spécifique sur l’interactome de Beclin 1 peut affecter d'autres voies dans le réseau du contrôle autophagique. Ces voies ne semblent pas suivre une hiérarchie linéaire, mais doivent être plutôt interconnectées dans un circuit complexe dans lequel la stimulation de l'autophagie par des déclencheurs physiologiques (tels que la carence en nutriments ou le stress des organites) induit un ensemble de changements intimement liés et impliqués dans une boucle de régulation positive qui constituerait un ensemble indissociable composant l’«autophagy switch». / Macro-autophagy is a conserved catabolic pathway that culminates in the degradation of old/damaged organelles,long-lived/aggregated proteins and portions of the cytosol for metabolic recycling to maintain cellular homeostasis.The absence of autophagy is frequently observed in many pathologies including cancers and neurodegenerative diseases. Beclin 1, a bona fide tumour suppressor, is the key autophagy regulatory protein that participates in autophagosome nucleation. Infect, Beclin 1 is a BH3-only protein that can interacts with the BH3 receptor domain contained within Bcl-2 and its homologues. This interaction functions as a inhibitory check on autophagy. Some pharmacological agents such as ABT737, referred to as ‘BH3 mimetics’, occupy the BH3-binding grooves to competitively disrupt the inhibitory interaction between Beclin 1 and Bcl-2/Bcl-XL allowing Beclin 1 to maintain the class III phosphatidylinositol-3-kinase activity of Vps34 for the phagophore formation. Autophagy is a complex process that is regulated by multiple protein complexes beyond that organized around Beclin 1. The energy sensors including AMP-dependent kinase (AMPK), mammalian target of rapamycin (mTOR), Sirtuin1 (SIRT1) as well as stress-integrating pathways such as those involving the inhibitor of NF-κB (IκB) kinases (IKK) and the tumour suppressor protein p53, all have a major impact on the regulation of autophagy. In many paradigms of autophagic stimulation, they all seem to act upstream of the dissociation of Beclin 1-Bcl-2. Our results reveal that ABT737stimulate multiple pro-autophagic pathways to be optimally efficient. These results place SIRT1, AMPK/mTOR,HDM2 and IKK downstream of the dissociation of the Beclin 1-Bcl-2 complex. This study advocates that BH3mimetics trigger multiple autophagy-stimulatory pathways maybe due to the high degree of connectivity that exists among autophagy-regulatory protein complexes meaning that a specific effect on the Beclin 1-interactome might affect other nodes in the autophagy-controlling network. These pathways cannot follow a linear hierarchy and rather must be interconnected in a complex circuitry, in which stimulation of autophagy by physiological triggers (such as starvation or organelle stress) induce an ensemble of intimately linked changes that are coupled to each other in positive feed forward loops constituting an indissociable ensemble that composes the “autophagic switch”.

A desregulação da apoptose, principalmente da via mitocondrial, exerce papel na progressão tumoral, resistência à quimioterapia, além de favorecer a formação de metástases por permitir a sobrevivência de células tumorais na circulação e outros microambientes teciduais. No presente estudo, foram avaliados 58 mastocitomas cutâneos caninos, provenientes de 50 animais submetidos à cirurgia excisional como única forma de tratamento. Os tumores foram graduados de acordo com o sistemas de estabelecidos por Patnaik, Ehler e MacEwen (1984) e Kiupel et al. (2011). As expressões das proteínas relacionadas à via intrínseca da apoptose, BCL2, BAX, APAF1, Caspase 9 e Caspase 3, foram caracterizadas por meio de imuno-histoquímica. Os resultados obtidos das imunomarcações foram comparados às graduações histopatológicas, bem como à mortalidade em função do tumor e ao tempo de sobrevida pós-cirúrgico. Observamos maior expressão de BAX em mastocitomas de grau III, bem como menor expressão de BCL2 em tumores de alto grau. A detecção imuno-histoquímica de BAX foi considerada um indicador prognóstico para sobrevida e mortalidade em função da doença, enquanto que as de APAF1 e BCL2 adicionaram valor prognóstico às graduações histopatológicas melhorando a previsão da sobrevida pós-cirurgia / Deregulation of apoptosis, especially in the mitochondrial pathway, plays a role in tumor progression, resistance to chemotherapy, and favor the formation of metastases by allowing the survival of tumor cells in the blood stream and other tissue microenvironments. In the present study, we evaluated 58 canine cutaneous mast cell tumors, from 50 dogs, which were submitted to excisional surgery alone. The tumors were graded according to the systems proposed by Patnaik, Ehler and MacEwen (1984) and Kiupel et al. (2011). The expression of the apoptosis-related proteins BCL2, BAX, APAF1, caspase 9 and caspase 3 was characterized by immunohistochemistry. Immunohistochemical results were compared with the histopathological grades, mortality due to the tumor and post-surgical survival time. We observed increased expression of BAX in grade III mast cell tumors and lower expression of BCL2 in high-grade tumors. Immunohistochemical detection of BAX was considered an independent indicator of prognosis for survival and mortality due to the disease, whereas APAF1 and BCL2 added prognostic value to the histopathological grading systems improving the prediction of survival post surgery